Adjunctive N-acetyl-L-cysteine in treatment of murine pneumococcal meningitis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4825-4830

  Högen, Tobias ^a   Demel, Cornelia ^b   Giese, Armin ^a   Angele, Barbara ^a   Pfister, Hans Walter ^a   Koedel, Uwe ^a   Klein, Matthias ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Klinikum Landsberg am Lech   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CEFTRIAXONE; PLACEBO;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BODY WEIGHT; BRAIN STEM RESPONSE; CLINICAL ASSESSMENT; COCHLEA; CONTROLLED STUDY; DRUG EFFICACY; EXPLORATORY BEHAVIOR; HEARING IMPAIRMENT; LONG TERM CARE; MALE; MAZE TEST; MEMORY; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; OPEN FIELD TEST; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; SCORING SYSTEM; STREPTOCOCCUS PNEUMONIAE; T MAZE TEST; TREATMENT DURATION;

ACETYLCYSTEINE; ANIMALS; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; COCHLEA; DISEASE MODELS, ANIMAL; HEARING LOSS; MALE; MENINGITIS, PNEUMOCOCCAL; MICE; MICE, INBRED C57BL;

EID: 84884278821     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00148-13     Document Type: Article

References (47)

1. Brouwer MC, Tunkel AR, van de Beek D. 2010. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin. Microbiol. Rev. 23:467-492.
2. Kastenbauer S, Pfister HW. 2003. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 126:1015-1025.
3. Brouwer MC, Heckenberg SG, de Bans J, Spanjaard L, Reitsma JB, van de Beek D. 2010. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 75:1533-1539.
4. Auburtin M, Porcher R, Bruneel F, Scanvic A, Trouillet JL, Bedos JP, Regnier B, Wolff M. 2002. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am. J. Respir. Crit. Care Med. 165:713-717.
5. Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. 2006. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol. 5:123-129.
6. Klein M, Koedel U, Pfister HW. 2006. Oxidative stress in pneumococcal meningitis: a future target for adjunctive therapy? Prog. Neurobiol. 80: 269-280.
7. Kastenbauer S, Koedel U, Pfister HW. 1999. Role of peroxynitrite as a mediator of pathophysiological alterations in experimental pneumococcal meningitis. J. Infect. Dis. 180:1164-1170.
8. Kastenbauer S, Klein M, Koedel U, Pfister HW. 2001. Reactive nitrogen species contribute to blood-labyrinth barrier disruption in suppurative labyrinthitis complicating experimental pneumococcal meningitis in the rat. Brain Res. 904:208-217.
9. Klein M, Koedel U, Kastenbauer S, Pfister HW. 2008. Nitrogen and oxygen molecules in meningitis-associated labyrinthitis and hearing impairment. Infection 36:2-14.
10. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, Pfister HW. 1998. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann. Neurol. 44:592-600.
11. Szabo C. 2003. Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett. 140-141:105-112.
12. Kastenbauer S, Koedel U, Becker BF, Pfister HW. 2002. Oxidative stress in bacterial meningitis in humans. Neurology 58:186-191.
13. Abuja PM. 1999. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 446:305-308.
14. Boje KM. 1995. Inhibition of nitric oxide synthase partially attenuates alterations in the blood-cerebrospinal fluid barrier during experimental meningitis in the rat. Eur. J. Pharmacol. 272:297-300.
15. Kastenbauer S, Koedel U, Becker BF, Pfister HW. 2002. Pneumococcal meningitis in the rat: evaluation of peroxynitrite scavengers for adjunctive therapy. Eur. J. Pharmacol. 449:177-181.
16. Koedel U, Pfister HW. 1997. Protective effect of the antioxidant N-acetyl- L-cysteine in pneumococcal meningitis in the rat. Neurosci. Lett. 225: 33-36.
17. Leib SL, Kim YS, Black SM, Tureen JH, Tauber MG. 1998. Inducible nitric oxide synthase and the effect of aminoguanidine in experimental neonatal meningitis. J. Infect. Dis. 177:692-700.
18. Loeffler JM, Ringer R, Hablutzel M, Tauber MG, Leib SL. 2001. The free radical scavenger alpha-phenyl-tert-butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis. J. Infect. Dis. 183:247-252.
19. Winkler F, Koedel U, Kastenbauer S, Pfister HW. 2001. Differential expression of nitric oxide synthases in bacterial meningitis: role of the inducible isoform for blood-brain barrier breakdown. J. Infect. Dis. 183: 1749-1759.
20. Kelly GS. 1998. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 3:114-127.
21. Grant LM, Rockey DC. 2012. Drug-induced liver injury. Curr. Opin. Gastroenterol. 28:198-202.
22. Millea PJ. 2009. N-acetylcysteine: multiple clinical applications. Am. Fam. Physician 80:265-269.
23. Auer M, Pfister LA, Leppert D, Tauber MG, Leib SL. 2000. Effects of clinically used antioxidants in experimental pneumococcal meningitis. J. Infect. Dis. 182:347-350.
24. Christen S, Schaper M, Lykkesfeldt J, Siegenthaler C, Bifrare YD, Banic S, Leib SL, Tauber MG. 2001. Oxidative stress in brain during experimental bacterial meningitis: differential effects of alpha-phenyl-tert-butyl nitrone and N-acetylcysteine treatment. Free Radic. Biol. Med. 31:754- 762.
25. Klein M, Koedel U, Pfister HW, Kastenbauer S. 2003. Meningitisassociated hearing loss: protection by adjunctive antioxidant therapy. Ann. Neurol. 54:451-458.
26. Barichello T, Generoso JS, Collodel A, Moreira AP, Almeida SM. 2012. Pathophysiology of acute meningitis caused by Streptococcus pneumoniae and adjunctive therapy approaches. Arq. Neuropsiquiatr. 70:366- 372.
27. Bonfanti L, Peretto P. 2011. Adult neurogenesis in mammals-a theme with many variations. Eur. J. Neurosci. 34:930-950.
28. Mestas J, Hughes CC. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172:2731-2738.
29. Klein M, Schmidt C, Kastenbauer S, Paul R, Kirschning CJ, Wagner H, Popp B, Pfister HW, Koedel U. 2007. MyD88-dependent immune response contributes to hearing loss in experimental pneumococcal meningitis. J. Infect. Dis. 195:1189-1193.
30. Koedel U, Winkler F, Angele B, Fontana A, Flavell RA, Pfister HW. 2002. Role of caspase-1 in experimental pneumococcal meningitis: evidence from pharmacologic caspase inhibition and caspase-1-deficient mice. Ann. Neurol. 51:319-329.
31. Koedel U, Angele B, Rupprecht T, Wagner H, Roggenkamp A, Pfister HW, Kirschning CJ. 2003. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J. Immunol. 170:438-444.
32. Koedel U, Rupprecht T, Angele B, Heesemann J, Wagner H, Pfister HW, Kirschning CJ. 2004. MyD88 is required for mounting a robust host immune response to Streptococcus pneumoniae in the CNS. Brain 127: 1437-1445.
33. Ferner RE, Dear JW, Bateman DN. 2011. Management of paracetamol poisoning. BMJ 342:d2218. doi:10.1136/bmj.d2218.
34. Demel C, Hoegen T, Giese A, Angele B, Pfister HW, Koedel U, Klein M. 2011. Reduced spiral ganglion neuronal loss by adjunctive neurotrophin- 3 in experimental pneumococcal meningitis. J. Neuroinflammation 8:7. doi:10.1186/1742-2094-8-7.
35. Koedel U, Winkler F, Angele B, Fontana A, Pfister HW. 2002. Meningitis- associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase. J. Cereb. Blood Flow Metab. 22:39-49.
36. Paul R, Winkler F, Bayerlein I, Popp B, Pfister HW, Koedel U. 2005. Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis. J. Infect. Dis. 191:776-782.
37. Deacon RM, Rawlins JN. 2006. T-maze alternation in the rodent. Nat. Protoc. 1:7-12.
38. Klein M, Paul R, Angele B, Popp B, Pfister HW, Koedel U. 2006. Protein expression pattern in experimental pneumococcal meningitis. Microbes Infect. 8:974-983.
39. Brouwer MC, McIntyre P, Prasad K, van de Beek D. 2013. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev. 6:CD004405. doi:10.1002/14651858.CD004405.pub4.
40. Caye-Thomasen P, Worsoe L, Brandt CT, Miyazaki H, Ostergaard C, Frimodt-Moller N, Thomsen J. 2009. Routes, dynamics, and correlates of cochlear inflammation in terminal and recovering experimental meningitis. Laryngoscope 119:1560-1570.
41. Heckenberg SG, Brouwer MC, van der Ende A, Hensen EF, van de Beek D. 2012. Hearing loss in adults surviving pneumococcal meningitis is associated with otitis and pneumococcal serotype. Clin. Microbiol. Infect. 18:849-855.
42. Tauber MG, Burroughs M, Niemoller UM, Kuster H, Borschberg U, Tuomanen E. 1991. Differences of pathophysiology in experimental meningitis caused by three strains of Streptococcus pneumoniae. J. Infect. Dis. 163:806-811.
43. Downs I, Liu J, Aw TY, Adegboyega PA, Ajuebor MN. 2012. The ROS scavenger, NAC, regulates hepatic Valpha14iNKT cells signaling during Fas mAb-dependent fulminant liver failure. PLoS One 7:e38051. doi:10 .1371/journal.pone.0038051.
44. de Gans J, van de Beek D. 2002. Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med. 347:1549-1556.
45. Bhatt SM, Cabellos C, Nadol JB, Jr, Halpin C, Lauretano A, Xu WZ, Tuomanen E. 1995. The impact of dexamethasone on hearing loss in experimental pneumococcal meningitis. Pediatr. Infect. Dis. J. 14:93-96.
46. Rappaport JM, Bhatt SM, Burkard RF, Merchant SN, Nadol JB, Jr. 1999. Prevention of hearing loss in experimental pneumococcal meningitis by administration of dexamethasone and ketorolac. J. Infect. Dis. 179: 264-268.
47. Kim HH, Addison J, Suh E, Trune DR, Richter CP. 2007. Otoprotective effects of dexamethasone in the management of pneumococcal meningitis: an animal study. Laryngoscope 117:1209-1215.